Cellectis (CLLS) 5 Nov 212021 Q3 Earnings call transcript

Company Profile

Participants

Andre Choulika	Chief Executive Officer
Eric Dutang	Chief Financial Officer
Carrie Brownstein	Chief Medical Officer
Yigal Nochomovitz	Citigroup
Gena Wang	Barclays
Kelsey Goodwin	Guggenheim
Kelly Shi	Jeffries
Hartaj Singh	Oppenheimer & Co
Jack Allen	Baird
Raju Prasad	William Blair
Nick Abbott	Wells Fargo
Ingrid Gafanhão	Kempen & Co

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Cellectis Q3 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. the Officer. to turn Dutang, host now Financial Chief will conference your over Eric I you. Thank

may You begin. now

Eric Dutang

conference you, Thank and results corporate welcome, third call. Cellectis quarter everyone XXXX and update to financial

September for Chief website nine-months with on me is XXXX. Choulika, are our Carrie XX, Yesterday Medical the reporting our today evening, period, its results Executive Joining and prepared on Cellectis press Dr. available Officer; and release at the filed call reports Dr. and press remarks Andre Chief ending cellectis.com. third Officer. quarter Brownstein, our These interim financial report releases our

most the As in December ending XX-F that reminder, plans. risks will Forward-Looking hand cause differ to may with makes development and to our forecasted. These its with be to financial over Statements XXXX, regarding subject would we actual in description I results the year XX, addition recent outlook product can the call those SEC Andre. of make these on now regulatory to like from statements the SEC uncertainties time-to-time. Form and A to from Cellectis and filings and manufacturing, are Cellectis found filed subsequent risks

Andre Choulika

everyone Good for Eric. thank us morning, you, and today. Thank joining you,

our and the grateful the far for our proud a XXXX partners Cellectis of year series been thus Over the third has team, quarter a the incredibly XXXX last has all course work achieved we and and of of and nine-months Cellectis. by achieved are productive of our key stakeholders. hard milestones

yesterday, XXrd of cell the for two to progress next fronts presentation the the release and disease. accepted share over of you Hematology are BALLI-XX Cellectis preclinical sickle at UCARTXX for significant acute data of leukemia trial Annual clinical we that all TALGlobinXX thrilled Meeting. patients from on or made the relapsed B-cell will Society have announced preliminary in We lymphoblastic half treatment American of hour. Notably, a abstracts refractory with that our presentation with present its data of additional Cellectis first

regard we have made targeting UCART product to focusing expressing CAR Additionally, UCARTMESO, on T-cell our pipeline candidate with preclinical tumors. notable solid with allogeneic our the progress solid document tumors,

preclinical future. to vivo and vitro share with anti from the be decision them In tumor will We in in Immunotherapy to This competitive Annual this the the therapy therapeutic developments RNA gene presented of Society production manufacturing to DNA, first and product. internalize the to owns with an course, commercial the to as our manufacturing the own our success of can ID Due our stage space. therapy our UCART's. an innovative and completion potential of our such create the XXXX, gene are world. Meeting made vectors, at cell R&D and cell data We clinical month. independence processes, both activity levels demonstrating therapy and and of supplies swiftly processes, crucial into excited facilities, GMP Cellectis Cellectis our manufacturing over in This owns its of Cancer transformative trials later in the in produce for our decision the investment a today's move products. control GMP to Whoever messenger provides revealed we cell facility advantage in process, of buffers at the

capable in bringing directly could from are barriers We the delivery and to manufacturing trial, to R&D new of believe competitors companies size are clinical moving only of of the We patient to one our IDs to into eliminating house some of that contribute be are all the proud innovative to that facing. in-house. manufacturing

are met and lead safety time and and production short consistency provide to is goal adaptability. and Our our

we need target edge at our the process. innovation cutting disease the manufacturing fully require level may of by our each capabilities, As master advanced therapies to

can we product that means clinical in-house candidates manufacturing registrational best responses, at the promising rapidly possible we our therapeutic leading filing. version having monitor to as Importantly,

for starting fully manufacturing Our now production the GMP tXhat is material. facility parents operational

facility On systems and remains third completed production side facility the Qualification was the track grounds in early successfully on of in of other of QX. UCART of the enable the qualification Raleigh second GMP our product equipment engineering start suite pond, manufacturing equipment UCART to the of XXXX.

Carrie, Chief like to Officer our clinical and over ahead. three Carrie the product sponsored please of would call I Dr. Now turn an preclinical Medical update to to give Brownstein, pipeline. trials go our

Carrie Brownstein

Cellectis and proprietary BALLI-XX with leukemia, MELANI-XX Thank malignancies. refractory acute evaluating B-cell our patients UCARTXXX CSX leukemia progress or trials evaluating patients three to relapsed myeloid lymphoblastic our relapsed evaluating you, in in or patients with Phase refractory evaluating X with in refractory UCART relapsed UCARTXX multiple therapies CAR continues hematologic acute Andre. allogeneic in clinical T-cell myeloma. AMELI-XX or

will Enrollment of refractory T-cell who support preliminary Andre year and proprietary additional to ongoing. programs first clinical clinical after and we our T-cell from UCARTXX XXXX Cellectis been in As has and and with mentioned, expansion busy preclinical and substantial patients additional a are after fludarabine, excited productive depletion our persistence. is data data at the with presented the for study Hematology, progress, with B-ALL share and The Society in relapsed the next patients The B-ALL abstract the alemtuzumab BALLI-XX patients received activity from results refractory updated label open trial of cyclophosphamide the is FCA escalation Annual of American was the study tolerated safety presented be relapsed dose data XXrd the at addition lymphodepletion. BALLI-XX UCARTXX and well in of deepened includes lymphodepletion X Congress. and promoted Meeting from FC preliminary month. alemtuzumab The Phase cohort making host CAR

gene derived with data designed homozygous autologous beta-globin a awarded candidate cell The be demonstration engineering subsequently to of A off to the from beta-globin itself in data presentation hematopoietic cells. progenitor the therapy and of sickle to The the engraft reversion and and phenotype, mutated and of in level at stem mutation vivo, that Hemoglobin level edit patient will TALEN gene poster expression Collectively product repair production used Hemoglobin efficiency as and development. based could or for A TALGlobinXX it ASH. obtained cleavage. the that best-in-class product sickle positioned TALGlobinXX and showed first in editing safety gene high presented data Additionally, was the of and disease therapy high restore HSPCs a target gene preclinical technology the the low demonstrate of cell gene patients be data correct the of sickling treatment anemia capacity

present pleased We in refractory patients share non-Hodgkin Phase lymphoma. the relapsed Data X poster non-Hodgkin refractory X in presentations. on Phase Allogene will evaluating that be relapsed will study from their partner multiple study our That from ALLO-XXX shared data at patients ALPHAX ALLO-XXX study the universal refractory lymphoma. evaluating oral data will with evaluating in with And ALLO-XXXA programs both from with our also ASH. are in present CAR Allogene licensed Alpha relapsed allogeneic Phase patients also to X a myeloma

group Meeting changes which product expansion anticipate for early T data myeloma. candidate we most first candidates for CAR of data UCARTMESO. T-cells CAR cytokines preliminary product additional two and of the with virtual new for is with T-cell dual pipelines and B-cell in target and multiple UCARTXXxXX trial Society and the activity. novel UCARTCSX the During the expressed drug product XXXX. targeting CAR presented enrolled of and highly T-cell two relevant non-Hodgkin validates allogeneic developed quarter patients of first solid a correlated is filing mesothelin robust inconsistently allogeneic therapy. translational in CSX allogeneic allogeneic persistence serum other a advancing gene we preliminary patients candidate UCART anti-myeloma UCARTCSX Cellectis UCARTXXxXX presented subset of the MELANI-XX pancreatic in was that applications the in lymphoma. observed as XXth is The one being and second XXXX, cell UCARTMESO over the also from tumors. associated cancer, an Annual is American and antigen a it of in mesothelioma of tumor at CAR is and expressed is in

of over please our to back expressing Washington XX, virtually that, is the mesothelin and for tumor at D.C. being solid mesothelin that November Cellectis' With suppression XX for CAR, UCARTMESO the on TGF will Dutang, In directed hand financials with XXth Immunotherapy leverages Eric presentation XXXX. in to Financial in call developed Cancers overview immune to by editing patients gene Eric a the activity Annual tumors. Officer of of Meeting UCARTMESO go beta. data addition ahead. preclinical initial also mediated support UCARTMESO to to quarter. I poster present Society an overcome Chief Cellectis TALEN expressing would like for anti for

Eric Dutang

of nine-months cash the from XXXX option financial assets proceeds including like Cellectis This and Calyxt April XX, as recent million December mainly $XXX as of the The to XXXX, used lease of expenditures, to equity as XX, was the Carrie. position share $X the million, of by selectee first September shareholders Calyxt in XXXX. to to cash loss financials non-cash based million restrict net per capital compensation loss you, were third million was XXXX, is Cellectis attributable in of revenues, to were assets million equivalents, $X share was Cellectis provide of position I excluding $XX share was and The of standalone that million million. net in Cellectis, cash consolidated million to cash adjusted lease net reflects million $XX $XX Cellectis our loss as of shareholders of The decrease million nine-months into million operating million a $XX compared a partially highlight The increase increase in fund was to which flows cash, the of income was decrease financing activities $XX the company’s million in nine-months net $XXX by compared proceeds I which exercise. of XXXX. $XX expenses September primarily per equivalents, partially This XXXX, quarter attributable flows $X.XX net gains to brief other a consolidated operations cash in $XX an to December The the or offset first overview $XX stock per financing and expected million excluding nine-months or at cash and of XX, Calyxt net loss compared XXXX. compared sufficient raised a in operating current of XXXX, cash, stock XXXX. Calyxt by XXXX. financial used attributable first $XX in financial million current $XXX XXXX. and of be $XX compared share Thank would $X.XX for $XX XXXX and to between consolidated to and the or investing first $XX and $XX cash nine-months XXXX. XXXX. by million and per from Calyxt an early of including of of million, R&D net of in and offset in shareholders in will activities excluding $XX difference net million million XX Cellectis position first This driven of was ATM $X.XX in program XXXX in of $XXX the expenses in XXXX,

fully laser cash spend in our our focused on manufacturing and candidates owned product clinic are Raleigh. the to We Paris or of our state-of-the-art facilities in in developing deep operating pipeline

please On With call Andre, would enable more growth other back G&A corporate maintaining go should Andre on ahead. and the end, the over expense. like hand to in to infrastructure our concluding efficient focus I for remarks. that, limited

Andre Choulika

Thank you Eric.

position platform that developing of the CAR us generation usher T UCART TALEN forefront therapies. Our the therapeutics next cancer in at novel of

look with in platform transform We QX transform At and leverage continuing of gene cancer we gene genetic and this XXXX to lives with to editing into serious effort develop forward of in proprietary XXXX diseases. rare and groundbreaking lives the medicine the patient development continue to continue patients leverage diseases. our we to editing expertise And to novel Cellectis, beyond. our to clinical

address patient clinic robust the clinical that, proprietary unmet the severe to call would with settings, With current focused disease. stage medical additional like we and for continue tumors, pipeline patient needs a are programs including the genetic of tackle advance solid advanced and And on with Our to to question-and-answers. oncology open I into to mythological malignancies.

Operator

a with Please with question-and-answer question. Instructions] Thank from you. At Our Nochomovitz proceed conducting [Operator this first question line Yigal will time, be the session. your Citigroup. of comes we

Yigal Nochomovitz

initially that you successful provide taking Yes had hi and ASH dataset? question that presentation more an for a as the detail on types very the much and the you the and of we question. bar Could bit qualify Andre data will respect to is internal thank UCARTXX would see I what data. in your team, a with

Andre Choulika

Well thank Carrie. you so question? this do I answer is take and probably like you the think Carrie, the person this question much to for question appropriate most to

Carrie Brownstein

Yigal, Hi from Sure you. absolutely. hear nice to

that what cyclophosphamide the So lymphodepletion planning we the were handful and is treated with showing first regimen. alemtuzumab, patients on of are and fludarabine

abstract will meeting. have had And the first the ready we the group you prepared of additional where we abstract, that in to in study. but the dose at for So is know the just we the phase still as are escalation data know,

are quite we not we a group very patients we an previous who you be patients, refractory a we So for CDXX to of where directed approval, in have have But know, so for relapsed need consider speak. bar we to what are as therapy. will

goal to would expect on as our be expecting So our we I'm move this for acute I product. development clinical tremendously for high. plan the shot with bar to speak not through first leukemia, so not

Yigal Nochomovitz

it. Got

thanks. for are To are can that the the to development? presented just question any (Ph). then the the you us preclinical set Okay, I clinical of features be data UCARTMESO give set you And data key [SITC] extent preview comment, on that could a that and the what of data that at supporting had

Andre Choulika

MESO? Carrie, describe want you also to do

Carrie Brownstein

Andre you position in better a to Yes. that. are I think do

Andre Choulika

Yes.

article, of receptor that the tumor is like, product is the other definitely have MESO you is T, and developing for tackling like types the without that this not only has, a like all that same of different a attributes were triple we the as would off shelf are think that T potential always tackle allergenic it type and microenvironment feedback that like of So down that something for with receptor is and the of of all first like solid solid MESO. there mesothelioma supposed also CAR is features That cancers, T-cells CDXX essentially for regulator on have big but like interesting the been that is that beta with this is of loop is be a will with is will an And It knockout all we that TGF trying the type one present I the work a show is developed also And in this but beta-X, And potentially you TME, as CAR protection. for be that in it platform in CAR the poke the MESO CAR in the lot example, into seen CAR to that holes complication is other combo the SAP CDC. microenvironment. plus targeting macro tumor tumors is the the shut it it to tumor beta developed environment. all of challenges type through a not on the knockout, selected sourcing is CAR the we blow have have, is going And the the probably SAP, a TGF is such to T down like will features will by we for of work shown cell. alemtuzumab which is extremely TGF so like is knockout. alpha, this that TCR that interesting this data one the that and which CAR for probably very give ASH negative

is T. it the triple its of CAR first kind think I knockout

frequent tumors. currently the I in like preparing the data theories of data definitely compelling compelling are as in into us results clinic as We for go well encourages tackling solid this and vitro gets and the are think to CAR vivo

Yigal Nochomovitz

you. Thank

Operator

you. Thank

with the Our comes your next from Barclays. Please question. proceed Wang Gena with of line question

Gena Wang

for a question. you few taking I model picture a have big regarding Thank questions. my

and one, Andre So the think call some maybe there wondering disclose had the I - Allogene clinical first your for come come but they much, translocation. earnings too about partner the it is didn’t that And and concern hold. the

programs events second your my regarding test then product, your through that? much translocation with the T read detect you you is in do how So and step question just how do the regarding approach allogenic each several CAR then And the general. wondering, also And regarding to your complete how and approach. the drug Allogene complete on this the would We see and data programs. we and response rate, like know your to companies letter, also of consolidation about partner apply the did see durability did some we improve share response any from faults don't approach, chromosome

Andre Choulika

for so much Well, thank Gena, you questions. the

let the the on allogeneic very definitely very that going the think commands think like of all, on their handling First work I are and we the making is fantastic the management I'm side. situation it confident to supportive critical Allogene because team hold is on of by I

are consolidation, definitely chromosomes help transformative Nevertheless, We UCARTXX they data are definitely special would or confidence will that to like this allogeneic this To product have are will there I strong non-human are. frequent closely, they where we state going showing chromosomal the extremely through this. it is we be quite but the a due to to excited in as the And And have impact as outcome population. in is to whatever aberration, much we on like on DNA recombination back aberration subjected ALLO-XXXA more are they the a data are allogeneic think very on we we definitely. come - resume we by helping CAR And go believe because situation actually. can, is the I certain trial period. this the and and this to is course, can of are the about we with monitoring like, speak Cellectis, the do

some undergo at these at and recombination of a and sometimes stage, DNA to immune lot changes recombination cells in this DNA T-cells stage can lead there. certain our normal a like So B

the first, in platform. be have. the that Like that said, patients - like should series have inhibitors, few product However, is the with danger things been of not dealt I same

on confident are stable. to editing, global very platform and where selected we be our develop gene not platform global only CART we So allogeneic the also but

line is no be allogeneic on in is turn especially beauty to is not allergenic something from T-cell all T-cells, an T-cell, thing has cancer don't, is going that an the in And that this cell of This never it adult is cancerous. and could general. happen like second there cells is approach cancer the happened gastric The finally, allogeneic T-cells about T-cell cancer, you it then adult cancer, donor, actually quite rare. history

quite So and this confidence we we that from and contrary stronger also this platform, are confident this phase come that have. what believe with will on lot with a we the of

no the on partners what doing. intermediate today have we on risk phase we that So concerns this like potential and an on And there. believe our Cellectis in are is

like with And transformative having, On focused very the driving been and also troops something so but positive saving the are that on for will many And the of our are data we that of partners have. IDs this and has products is very remain size contrary, not company, definitely is same in outcome Cellectis I are and we incepting. the target of and these the old life that producing. only the products, that technologies think type

But speaking strong Carrie and consolidation about have have been than but have is medical Now and interesting be more have I a doctor. this together, fresher to been on have it studies Gena could the like like Carrie’s and fears consolidation the I because always myself I a view, we think advocate. eye study something discussed very

words say this? So you to a want Carrie, few if about

Carrie Brownstein

you nice as to Sure, well. hi from hear Gena

that the So treatment. I'm all the presentation really includes consolidation about excited

treating half the to think I T-cell whether successful chemotherapy, to I are do being doses. to key a you any additional all with therapies We you year the measure the additional And fact as Cellectis using survival but a I of using anymore, of and that And since And you well and you I of the can't that give the these for these and can is that potential don't whatever know and patient have beauties whether molecules, a of has joined is that cancer the going see treatment, get the are antibody you them points think the main as anymore. CAR that you small that you them one is duration a make it huge only that diseases, that longer their is, therapies, can the setting. drawbacks one are ago. using allogeneic history to the not bring cure. remission their to able whether now cells this saying been their of oncologist state deeper longer

always treatment it that these therefore, of therapy make setting So is right way is able to patients one able and to go giving a is larger more see than have in excited additional you for to treatment when showing being difference finally And the to patients. really it who can. the really in received allogeneic datasets

Gena Wang

Thank you very much.

Operator

Thank you.

Our proceed next question with the Guggenheim. Michael line comes question. your Schmidt of with Please from

Kelsey Goodwin

is two Kelsey questions. for ones. Hey quick I for our this on Thanks taking Michael. have

field provide kind some existing guess, other ongoing so just remind just the UCARTXXXn in of differentiation Thanks and on areas where the then program, key the programs First, you versus at so And competitors T of of that? with CSX. you CAR much. how TALGlobinXX the us I to respect think are with you kind could could you color about

Andre Choulika

and give on Carrie, do for an you update give CSX, I want update can an to TALGlobinXX. XXX

Carrie Brownstein

is That perfect. sure. Yes,

Sorry, on for a I mute was Yeah. second.

will refractory first. and So start I for for that with AML relapsed UCARTXXX the - for one

So has through that dose been we study, said, escalation. as moving

you be think space sick know, who little with a with would fragile lymphoblastic as leukemia you acute than to more or see a patients tough I with tend AML and lymphoma. are quite is

are we additional year. are some next to point through but have at longer, bit dose escalation data a we hoping moving and taking is it So

everyone. We with will see to share

well requiring additional FDA for safety UCARTCSX forward. move of reopened you we to study for for clinical we some as as We safety the hold. guidance as adverse as adding some rules that that as been had the on ensure was - far you pieces treatment events, know, other too, As after protocol changing myeloma the

been have investigators. through lots data additional There we So next is been all later we be our of again, able program another nicely. escalation. from show this along moving that too, dose hope year. And moving to And of that to has is interest

data As that hold, before know, response. the that it did earlier year, translational present the that dataset you shows first did from the some which And included translational see. this of expect all we see original some show did we cells, expansion the interesting cytokines data we to the

are forward forward super we right. So excited and is when time about this are program move the continuing to data share looking to

Andre Choulika

Thank you, Carrie.

On on have, that of thalassemia for or big the TALGlobinXX current which disease is differentiation or reactivate type repressor knockout sickle the side, based hemoglobin of you beta hemoglobin. the we to one cell most that beta-globin of sickled a trials the tackling is different see

in So the you cells. sickled keep hemoglobin the

trials. mutation What results is out if that which the sickling the not would editing a is of point hemoglobin be there on figure fixing that destroy induces with mutation another not gene, is there and gene finally restore to And could gene, reactivate like gene be back they imagine of destroy is gene is which that the can repressor. one that people is works a have supposed an You a the mutation people been another produced sickling the these kind that in the so imagine phenotype, cells the editing, a to so there that in far. is are that most actually happening is be gene disrupted mutation expressed, what

mutation the scars Cellectis B adult approach scars or in DNA. fixing new in is repairing the and cells mutation leaving this So gene, to is any the hemoglobin and the the in the restoring Hemoglobin taking without

supposed is the gene to approach. it So you to an the This put was back be. sequence

very fixed not, but side with very technology talent Cytovia we are we our the and repaired approach are technologies gene with target in there are are hemoglobin on of it Cellectis very that a of with hemoglobin electrician and the which We high select there technology very field effects a totally this the developing have reduced at to engine the and adult is competition such this believe a course, is around repair accurate that cells level - end. high we approach brings

that in hemoglobin we most is So currently you is differentiate fixed. and believe patient clinic that approach to of this the be what that see what wants us their for their

Kelsey Goodwin

Great.

Okay. you Thank so much.

Operator

Thank you.

proceed comes with from the your question. question Kelly Shi Please next of line Jeffries. Our with

Unidentified Analyst

you Hi this Kelly. the Thank on Dave taking question. for for is

on through. prior Is possible Just outcome and could things reason directly this provide CAR option like lymphodepletion unexpected the quick it patient had that question Can include some Allo treatment? for you. ASH read be you CDXX who other is that detail regimen data. the for another CDXX T Thank

Andre Choulika

thank very could a ask to you Like antibody the was her like just mean inversion you much monoclonal the question. Well that or induce for that chromosomal an CDXX like is precision like a aberration question? somewhere

Unidentified Analyst

Yes.

Andre Choulika

this, seems It a observed such is and not the something part question on as about second especially aberration potentially not that that but type is to often like only non-internalizing and to complex, chromosomal might induce lot mechanistic classical I I the general. global of Excuse to to population. it locus quite is a not have a not are just out. or extremely is not part by side. It in unlikely is changes susceptible alemtuzumab generic the quite the me patient, but like me, such not observed of of there. all that but whole, It stepped for has personally, information a been antibody of chromosomal So alemtuzumab in

Unidentified Analyst

question ASH treatment? if of is, you part any with any you provide update. CDXX T second color CAR can The Do on the prior data on patient

Carrie Brownstein

story all included treatment treated dataset. To whether long group include of next past make otherwise answer abstract patients prior was can the of it that. the their in CDXX, past therapies, the their be history, short, ASH I will prior medical or will study on

to focus be directed will we patients speak who going included. have think to therapy. I types those patients. data patients. to the on not the study And do we in disclosed trial today, We have prior what or escalation, only to proportion types limiting of that not designs CDXX terms already those those patients, our are So I'm had But of allow expansion, in going of the are dose but of we

Unidentified Analyst

you. Thank

Carrie Brownstein

Sure.

Operator

Thank you.

line question with Singh of Oppenheimer next Please the proceed from Our comes question. Hartaj with & your Co.

Hartaj Singh

of thank just questions. update. is got follow-up the a and project. on for Great, the the couple One thanks you quick CDXX I

those loss. of subset, CDXX of an subset. don't directed could a the is is that a that that therapies expansion approval, that in a have in is antigen are relapse accelerated see patients dose for it sort also responses. Some all And if of that therapies, you CDXX good an that of know directed assuming patients if example, for like be biomarker, I

So then number these two, your And it with affiliates, that one. really is terms of solid interesting. in number is tumors

planning You you among believe solid forward with in clinical to PDL, a years cancers. with approved can CAR PD-X this various tumors mean, how the in development data four I T. pre-clinically talk you PD-X three to immunotherapy the X in X but in But I Phase specifically allogeneic could were have this looking as Andre, work. Phase the and and first initial are spoken earlier,

success a period? just be, to Any move in assuming to faster. seem you on can like, program you terms Any seemed what Solid see development thoughts could in middle thoughts be, can look of, you there move there you. faster. tumor the Thank early

Andre Choulika

question like I to the this a the it all part for of part in maybe get questions. And lot. great I'm can question. to your you the And going question question first the guess two Carrie the knows answer to because Hartaj can she so Thank she answered of split also answer

Carrie Brownstein

answer, did. but Yes some I or I maybe won't I will

Andre Choulika

for I Carrie. can work believe certainly I both,

Carrie Brownstein

Yeah, sure.

part So about question the the of CDXX. first

point. But no, a the is that directed doesn't relapses not therapy has antigen a law. everyone and or think I good respond CDXX who to So

not I XX% think the somewhere between numbers, a a said, necessarily if That I'm call and get is to mistaken, XX%. wouldn't but I that in will biomarker, that second. I

would, you of and tremendous data there set in but some is not after no, therapy is the of have UCARTXX there for data when a there we as a is seen the it have leukemia data directed obviously we data CDXX is survey, not as from So as of a lymphoma. amount that blinatumomab

to one a So been about to said, know as patients and program go, we get my a to therapy have it the of for have it well from terms and is that we while nation would to be something. another. try you to that compare the that to know, it it amount response BLA. can open the plan extremely as is into is But risk, super a rate go for bar exactly possible is place a the where see in vacation, dataset plan, from as get low hard of the the as quickly small this And development that group very as this patients of data what is

that focused group design and interesting patients good clinical expansion to it an is reason we a therapy that product that is to are we that could that quick. piece our for said, trial of is. the depending absolutely, a focus needs gives the so on And is to such on, because how help quickly it know us our is bring data and needs in on it market That group group, really

who works patients failed. in it show even CDXX it is who activity, in may have failed, loss, they haven't So dramatic and even if patients have maybe also

So these gives spaces And super the kind super, of an important. treatment to paradigm think it is move into multiple opportunity in patients. us for I

and it makes if also yes, but yes yes, is So, that know and sense.

Hartaj Singh

just the tumor And on question. solid

new expressing get thoughts way this of for Just your cancers? broadly, whether if in doing you any accelerated into and clinic, the over potential to want approval

Carrie Brownstein

Yes, and a do accelerated the going for always we be first It is the a I data to program while approval, we but And multiple chance for plans, looking have program yes, look development, different the get we obviously, really see. I do it exciting. that will hard be going interesting that until can from when I'm we it we see. avenues setting. to make take. to mean, think, an clinic see calculation, mesothelin And in targeting the is on and and all an mesothelin allogeneic I do what my think to however, really I how into clinical is into depend

one could see I would to accelerated is where over of for I quickly getting there consistent option would and proof isn't specific market and looking your bigger also we a larger go staggered path whether and broader highly for of have mesothelioma for example, be of that. that fast be and approval share and a ton there ways looking So likely things options, one. concept expression be indications like specific and would cancer clear, can there you an where or is approaches where

into a looked would program. of that will be putting all be together and comprehensive we So

of quickly can efficiently. that ways we So doing find and

Andre Choulika

of or enter interesting to blockers not of the the is PD-X by tumors, solid itself can tumor the cancer the are cast. XX% they tumors, is there. by to problem The continue system so into of protected is PDLX get cells enters and grow solid difficulty that antibody because What associated immune do the immune like monoclonal The they the into like respond access. that fibroblasts that, protected

the So SAP is this it and approach grasp not really CAR type transformative. really, have type is of that definitely today describing approach cannot wise is the concept potential we of can very I is a to on up think the expand in cast if of could with blowing can a be these that transformative what be the combos Carrie

Hartaj Singh

Great. thank you thank you Brownstein. Andre, Dr.

Andre Choulika

Sure, thanks.

Carrie Brownstein

you. Thank

Operator

you. Thank

comes question. Baird. the with line Allen question your next Our Jack with proceed from Please of

Jack Allen

going we much product could any I And you the to nature avoid question. But so Hi regard regulators are had thank Allogene? you as requests provide instances guys specifications ongoing Thank for taking know additional one taking update past here. so without have on of any or question. anything for this we you hold much to one. wondering was specific I for just Allogene’s and FDA I the commenting if with that regulatory you move with had interactions brief

Andre Choulika

is competitive Jack anything. - we we to Hi any doesn't FDA these question the some I a fully, into under, these so confidential that a of share also are much fluid to simple particularly, so very It are I change lot don't regular for because a and basis are is this. the answer you haven't so exchanges But going that advantage reason change is on have there hard seen thank interaction - for with a question. and selected. the guess things far, want it today significant to

that track this. think Excuse it very than So me, to more trials. is daily but to situation share it a is I like basis, on good far the our on with monitor important difficult Cellectis but a is so own

Jack Allen

much. Alright so Thank totally understand. you

Andre Choulika

Sure.

Operator

you. Thank

the proceed William comes Raju of with Our from with your question Please next question. Blair. Prasad line

Raju Prasad

as about Thanks BALLI. the for In of the wondering for context put And Thanks. FCA next XXxXX, three patients committee candidate said I UCARTXX the question. do discontinue, taking the the that the just gen abstract why. ASH we think to I in into was development?

Carrie Brownstein

Andre I one. can take Sure. this

other patients, the abstract additional patients our the first includes the And So data there. in in three will that be will patients, we all abstract meeting. presentation have the at

sort don't want all to for the I So reasons discontinuation into get of in that could dataset. be

say the far been is dose this reached suffice the to is Now, for And that Phase I activity rituximab different have patients as we Rule cells. was CDXX would our can and that recommended of will still in floating haven't lymphoma, we X the it on since first we differences bodies dose since mean, we has up be our And important or deactivated shown UCARTXX, our as part it patients so to board. why think But most will in big XXxXX, yet, for use killed to to as that escalation study. which patients rituximab therefore share why programs are will Embargo of again, on And can't rituximab reasons of longer, can would and as and one really be the know the months I in has it, I first, be with is dataset. board. and - are so our on you around materials six there, potentially there potentially I think, diminish it well

do to want lymphoma. wouldn't we So that for

not does differentiate to what's positioning rarely cause for are but the issue rituximab really an we is only fantastic UCARTXX because would there, has which ALL, is opportunity dual and ALL used itself for card with really an because in from rituximab. So XXxXX, but that, not of out it therefore leukemia,

Operator

Thank you.

Our next question question. the of your with with proceed comes from [indiscernible] SMBC. Please line

Unidentified Analyst

you question. so questions. for have I much my two Thank taking

color on second First, had that CRI. is one wanted you said reduction the UCARTXX this consistent some data. is abstract patient question CRI. your data from additional And then I data from get a glass the ASH reduction for to you some competitors. track ASH, for on very a that IND you next just comment preclinical clarification just also will Could with Were confirmed and present differentiating compare you encouraging could on CRISPR still preclinical do at is really programs But blues is also competitive TALGlobinXX and to how see and year? the foot on provide

Carrie Brownstein

Yes.

with So start the UCARTXX. I part the can about question first of

was. to what trying I'm the exactly remember Now company

Unidentified Analyst

question just or? so the reduction consistent not with from come is the CRA Sorry, CRI

Carrie Brownstein

is or confirmed Yes, as response not it confirmed criteria. the in is well, the with not the thing depends of it all same such is on, thing leukemia, no terms as there

is you see response actual patient criteria the will was, their it being not we impressive the response and which and on data, are can criteria you used, you leukemia, say. in present dataset, when it it as which however depends whether reduction blast few. what sort of, use, it a So CRI the quite or a on was count what is and had let's And depending in there

one each also a, of there just other it measure and status was the [indiscernible], with it the inotuzumab, them example, with unfortunately, different we But which one long unlike has for checking like, dependents the on bone are day. marrow NCCN, not how can which the what So used in is we Leukemia is the for resist, is for. were modified you was what using, every

exactly know criteria. whether not to or it hard really meets is it certain So

Andre, don't at So And But there. that know pretty you cagey if is with extremely And very our then patients is of extremely which TALGlobinXX. to it our level first treated lower dose why opinion. my amazing, and I is in we answer in it were to encouraging with group want FDA, I a careful speak think is kind data of interesting.

Andre Choulika

go the work probably is all package. to internally. will this the And TALGlobinXX the GMP through will but we are that the finished once the manufactured, done is is IND released. requirements next manufacturing, product be with material preparing Yes, start the currently we This to all something start once being year have

So quite clinic. into it not And a definitely the that I'm it will but is go exciting. IND is today, guidance that for something product filing giving any

Operator

you. Thank

your Our question. next proceed Wells of line with from question comes Fargo. with Please a Abbott Nick

Nick Abbott

you. Hi, thank

just question, presented. to back going data be what First the abstract in ASH will

I cleared I X.X and will next there the when is mg have ml you dose kilo that you you per on? have five million and Thanks. per step and a per think expect not, do if kg So do follow

Carrie Brownstein

next is and was Sure. already to I the pointed don't mean, presenting cohorts into be the ASH, datasets to would the unless million exactly again, I X.X really the get Rules going in out it one I in the which But we dose the was abstract that been which released. is be Xi given want Embargo two what five, the level are that stage and and for yes.

Nick Abbott

that absolute at range there to Is bottoms no the out I data only on in account it have wanted, have abstract, or the reduction, nine-days would profile, infusion? are bars shows of the the a before ALC XX. the is infusion the after but of expected out And that then infusion profile XX% Thanks. just pretty at time on bottomed you CAR

Carrie Brownstein

not I being have the went the to looking pull the alemtuzumab. up But tell lymphodepleting I patients exactly way it at all what can and is zero the it are you is is maybe with to you accurate, what because interpreted.

UCART So you is expansion. other may which line, be the at the looking

Nick Abbott

line looking blue is NO. which says counts? I’m lymphocyte that the at

Carrie Brownstein

front the to that But what counts, from it tell in cells I one to have send measuring with email but it depends of that have was on actual have me. in pull in to absolute back lymphocyte up cases it which get is UCART it. are I and will do a Yes, I actually what at Oh, I we can data measured it it clarification. know up, explain so I looking open I of at shown. it can was the know is are look patient to what and we and can where the but I look the you being some you don't

Nick Abbott

pretreated is obviously population. heavily a one very last Maybe

As think and I median abstract last five is the versus year. at you three said, ASH

this think so, I you and a trial, have is we five mean, a of Do population. the no challenging apparently benefit is very is already has still had place. obviously from since about there the can As you a T population CAR expansion, patients, medium who alemtuzumab they and if because here the depletion. kind CAR failure complete patient priors a that you in lymphocytes, the with but successfully is It T, no think it that is

Carrie Brownstein

Yes, it is question. a really good

our goes is to can a And think of to be is with shot if cohort, has multiple leukemia, important and comprehensive, this while and think think we I that to particularly our you in younger, to do. what But think product. this healthier given have multiple typically approval, is size, that disease able something definitely that I of that a even plan it I really (Ph) goal before, wanting to on a [VLA] I it on It answer, said bring the multiple, therapies. have the product people. had though, mean believe. And I you yes. go for to and development is is information I any clinicaltrials.gov, I expansion

super well. majority are good life somewhere not patients frail, long is them most can to are that be vast most is leukemia, otherwise people, speak focus one they're super is patients it shape to organs had is, and of XX, to more, of can leukemia Well cancer and we are hopefully super are they in so that good going adults. a to younger, most and over shape. but a keep matter, is even multiple their important. super the it for Generally children, And common young the they is work continue multiple our it as of in common speaking, don't in to cancer arms, are therapies, for development maybe over myeloid really like program therapies, have it and patients XX, to or bring on this where have where these So taking who cure think and for acute I

is diseases than these people. So a I talking in think a myeloid story of or ALL see particular, about little are bit in that you of it you older leukemia, when in different some other

failures. a I potentially CDXX have we would faster be think younger, in and our strategy to where market directed expansion, would So in want these

are life. can really be have So can with exception otherwise, therapy need need move something of and and well forward the still treated it is still leukemia and that they and need a their to potentially a

for and us that. So that small of though, vacation in nation how and about doing other we strategies is can therefore, plans we go terms development where other it said, are else would a in go place and

So bring CAR people to not already. potentially, we can to therapies your also point, larger it who T a necessarily group. have And failed failed by and

Nick Abbott

Okay. Thank very you much.

Carrie Brownstein

thank you. Yes,

Operator

comes Our your Gafanhão final line question. the of proceed Please from Kempen. Ingrid with question with

Ingrid Gafanhão

then. questions. thank team bit you will taking for Hi brief my I it a keep

you scaling do plans checking, Just with of are ship. to your shareholder and once what want your again, you check

to I to this are the you monetize keen say will in let's any be you mid-term? mentioned you to it. think short maintain But planning

Andre Choulika

was not about is your Hi what? Ingrid. of clear. I missed the question super It actually beginning

Ingrid Gafanhão

shareholder and your meant ship? check your with was current what on to is I thinking Calyxt you,

Andre Choulika

transform that been change Director think, not has in by only arrival believe the is changing we company but currently, chairmanship and also a into of of change about of a induced significant leadership by leadership, meaningful very this with Cellectis Calyxt. we Yves and the the the Carr, under the Board Actually, Calyxt new Ribeill, strategy also that announced just And a has to Michael manner. stake

the I to market. lot a it you fact positive since the of by and that this we well are then, received that bring think is quite been has value going that on see

us be the of as interest believe future As for a shareholders Calyxt. is like to I waiting is in valuable up vested very success that said, in the has And Cellectis is and we of definitely Calyxt to going it this. something

to advantage. implemented. very company And time up and current strategy the this to believe the should have wait very that swiftly, strategy we to we new our pieces So in the has be to is extremely this of rapidly changing implementation which all successful lead the

Ingrid Gafanhão

if are one some is considering programs planning just on just year, providing burn? I clear. looking Eric, you are more forward Thank have that you, next any into And question cash may move INDs guidance your you ahead for to that

Eric Dutang

our we any provide What say, cash burn. on on way the management Cellectis. payments. guidance is don't We we XXXX cash run And don't disclose early

up get we We we programs XX up and where get with $X targets. with on million XXXX to (Ph), have where can the $XXX to Allogene partnership also billion [UCLA] from partnership can

Andre Choulika

is cash And paid, be A also translating series but vast, XXXX was unchanged. into it of is and IO titled the milestones flow to

Ingrid Gafanhão

much. you Thank very Alright.

Andre Choulika

you. Thank

Carrie Brownstein

Thank you.

Eric Dutang

Thank you.

Operator

Ladies Andre remarks. over session. we have will closing and gentlemen, end of I the reached for the question-and-answer the turn call to Choulika now

Andre Choulika

you thank everyone this Well, very for Q&A. much

our at trials questions excited trials. of and shop course, one-stop years for partners these Z with of I have with therapy, going CAR lot T we company Cellectis, what company, Thank think please think fide all Carrie, as a at come a Cellectis you. is and are in and like strategy been gene and editing the that very true so to and things sharing and our manufacturing. comes have oncology next is watch to leaping this I is much. seriously a in We clinic gene and are making There extremely that transformative we becoming Cellectis and waiting a a with excited it turning like things that posters to from at closely you point, is meetings and older change the A coming biopharmaceutical of the point And to months ASH, our with internalizing for powerful ongoing bona

Operator

may disconnect time. and This a you your and wonderful lines participation you your day. at Thank for this concludes have conference today's

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.